

Lifetime Probability of Developing (2018-2019, 2021) or Dying (2020-2022) from Cancer, US

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All sites^a	39.9	3	17.2	6	39.0	3	16.0	6
Brain & ONS	0.7	154	0.5	205	0.5	192	0.4	248
Breast	0.1	755	<0.1	3,793	13.1	8	2.3	43
Colorectal	4.1	24	1.5	67	3.8	26	1.4	72
Esophagus	0.8	132	0.6	158	0.2	437	0.2	563
Hodgkin lymphoma	0.2	446	<0.1	3,092	0.2	536	<0.1	4,355
Kidney & renal pelvis	2.2	45	0.5	199	1.3	75	0.3	356
Larynx	0.5	211	0.2	637	0.1	875	<0.1	2,505
Leukemia	1.8	55	0.8	128	1.3	77	0.6	170
Liver & intrahepatic bile duct	1.5	68	0.9	108	0.7	143	0.5	185
Lung & bronchus	5.8	17	3.7	27	5.6	18	3.5	29
Melanoma of skin ^b	3.5	29	0.4	269	2.5	40	0.2	496
Myeloma	0.9	108	0.4	260	0.8	133	0.3	309
Non-Hodgkin lymphoma	2.3	44	0.7	154	1.9	54	0.5	194
Oral cavity & pharynx	1.6	61	0.4	249	0.7	139	0.2	542
Ovary	--	--	--	--	1.1	89	0.7	140
Pancreas	1.7	60	1.3	78	1.7	60	1.3	78
Prostate	12.8	8	2.0	49	--	--	--	--
Stomach	1.0	104	0.3	292	0.7	153	0.2	405
Testis	0.4	248	<0.1	4,625	--	--	--	--
Thyroid	0.6	160	0.1	1,913	1.7	59	0.1	1,513
Urinary bladder ^c	3.4	29	0.8	132	1.1	93	0.3	337
Uterine cervix	--	--	--	--	0.6	156	0.2	186
Uterine corpus	--	--	--	--	3.1	32	0.7	154

^aExcludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

^bStatistics are for non-Hispanic Whites.

^cIncludes invasive and in situ cancer cases.

Data source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.9.0, National Cancer Institute, 2024.

